H.C. Wainwright assumed coverage of Ultragenyx (RARE) with a Buy rating and $80 price target The firm sees an attractive buying opportunity with the shares down 35% year-to-date. The Orbit trial did not fail and the final top-line result is risk-mitigated and should deliver favorable data, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx’s UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained
- Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
- Ultragenyx participates in a conference call with JPMorgan
- Ultragenyx price target lowered to $79 from $80 at BofA
- Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval